Truist Securities Downgrades Evolent Health to Hold, Maintains Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 87.6%

Neg 87.6% Neu 0% Pos 0%

Truist Securities analyst Jailendra Singh downgrades Evolent Health (NYSE:EVH) from Buy to Hold and maintains the price target from $7 to $7.